Catalent Pharma Solutions (Booth 1546) has appointed Sally Langa to the position of vice president, business development, for Catalent’s development and analytical services offerings. In this role, Ms. Langa will be responsible for growing Catalent’s early phase development business for small molecule compounds, including analytical services, formulation development and micronization.

Ms. Langa joins Catalent from Halo Pharma where she held the role of vice president, sales and marketing. Her career within the pharmaceutical services industry, which spans almost thirty years, has also seen her hold a number of senior positions at Patheon.

“Sally brings a huge amount of experience to Catalent and will be a pivotal part of the team charged with meeting the company’s ambitious growth targets,” said Jonathan Arnold, vice president and general manager of advanced delivery technologies, Catalent. “Catalent sees great growth potential in its early stage development activities, as well as continued opportunity to integrate these services further into the clinical and commercial phases of development.”

Ms. Langa is an active member of the Drug, Chemical and Associated Technologies (DCAT) Association, and is currently on the technology committee. She is also a trustee on the board of the Pharma & Biopharma Outsourcing Association (PBOA).